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Pancreatic cancers (PC) are highly metastatic with poor prognosis, mainly due to
delayed detection. We previously showed that PC-derived extracellular vesicles (EVs) act
on macrophages residing in the liver, eliciting extracellular matrix remodeling in this organ
and marked hepatic accumulation of CD11b+ bone marrow (BM) cells, which support
PC liver metastasis. We here show that PC-EVs also bind to CD11b+ BM cells and
induce the expansion of this cell population. Transcriptomic characterization of these
cells shows that PC-EVs upregulate IgG and IgA genes, which have been linked to the
presence of monocytes/macrophages in tumor microenvironments. We also report here
the transcriptional downregulation of genes linked to monocyte/macrophage activation,
trafficking, and expression of inflammatory molecules. Together, these results show for
the first time the existence of a PC–BM communication axis mediated by EVs with a
potential role in PC tumor microenvironments.
Keywords: tumor microenvironment, extracellular vesicles, macrophages, monocytes, metastasis, pancreatic
cancer, exosomes, cancer
INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the world, displaying a
5-year survival rate of about 6% and a median survival rate of about 6 months. Among pancreatic
cancers, pancreatic ductal adenocarcinoma (PC) is the most common type and accounts for more
than 90% of cases (Saif, 2011). A combination of factors leads to the poor prognosis of PC,
including difficulties in detecting early stage disease, its high metastatic potential, and its resistance
to conventional therapies. Current predictions report a worldwide escalation in the incidence of
this disease and an over twofold increase in the number of new PC cases, as well as related deaths,
by 2030 (Ying et al., 2016; Foucher et al., 2018).
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Tumors do not exist as isolated entities, but as complex
systemic networks involving cell–cell communication between
transformed and non-transformed cells. The milieu created
by tumor-associated cells can be composed by both local
cells and cells recruited from distant sites, such as the bone
marrow (BM) (Bergfeld and DeClerck, 2010), creating a tumor
microenvironment thought to be a key modulator of tumor
progression by providing either inhibitory or stimulatory growth
signals (Bissell and Hines, 2011). In sites distant from the
primary tumor, non-tumor cells can also be hijacked in order
to prepare the future metastatic sites that support engraftment
and survival of metastatic cells (Bergfeld and DeClerck, 2010; Lee
and Margolin, 2011). Besides direct cell-to-cell communication,
secreted factors play a key role in the interaction among cells.
Of these, extracellular vesicles (EVs) have emerged as novel cell–
cell communication players in setting up and modifying tumor
microenvironments (Record et al., 2014; Maia et al., 2018).
Extracellular vesicles are vesicles released by both prokaryotic
and eukaryotic cells, being involved in various physiological and
pathological processes (Kalluri and LeBleu, 2020). Microvesicles
and exosomes are prevalent types of EVs in biofluids.
Microvesicles are generated by the direct outward budding of
the plasma membrane, and they range in size from ∼100 to
1,000 nm (Stahl and Raposo, 2019). In contrast, exosomes have
an endosomal origin and fall within a size range of ∼30 to
150 nm in diameter (Maia et al., 2018; Stahl and Raposo, 2019).
Regardless of their type, EVs can harbor biomolecules such as
proteins, DNAs, messenger RNAs, microRNAs, and other RNAs
(Nolte-’t Hoen et al., 2012). Due to their cargo and capacity to
transfer information both locally and to distant sites, consensus
has lately emerged on their role as “signal-transducing agents”
(Stahl and Raposo, 2019).
The role of EVs in oncology is currently an active area of
research. We have recently described a previously unknown
prometastatic circuit in which pancreatic cancer-derived EVs
can induce the formation of liver premetastatic niches (LPMN)
that foster metastatic development (Costa-Silva et al., 2015;
Hoshino et al., 2015). We demonstrated that EVs derived
from malignant pancreatic lesions play a key role in LPMN
initiation by being specifically taken up by Kupffer cells (KC)
in the liver, where they activate fibrotic pathways and promote
a pro-inflammatory milieu that ultimately supports metastasis.
In particular, we showed that exosomal macrophage migration
inhibitory factor (MIF) induces the release of transforming
growth factor β (TGF-β) by KCs, which, in turn, promotes
activation and fibronectin production by hepatic stellate cells.
Fibronectin deposits subsequently promote the arrest of CD11b+
BM-derived cells in the liver, completing the formation of the
LPMN (Costa-Silva et al., 2015). Although we showed that BM
cells are a key component of the LPMN, it is still unknown
whether PC-EVs have a potential direct effect in BM cells and in
their phenotypes.
Considering that virtually any cell in the body is a potential
target for these tumor-derived messages, the identification of
novel cellular circuits induced by tumor-derived EVs will help to
further elucidate the cellular mechanisms involved in oncologic
diseases. In this work, we show that PC-EVs preferentially bind
to CD11b+ BM cells and induce the expansion of this cell
population. Additionally, PC-EVs induce phenotypic changes in
CD11b+ BM cells with potential relevance to the dynamics of the
tumor microenvironments. Together, these results demonstrate
the existence of a PC–BM communication axis mediated by EVs
with a potential role in PC tumor microenvironments.
MATERIALS AND METHODS
Cells
The C57Bl/6 murine pancreatic adenocarcinoma PAN02
(also identified as Panc02) was purchased from the DTP,
DCTD Tumor Repository, NIH. Cells were cultured in RPMI
supplemented with 10% fetal bovine serum (FBS, Biowest
S181BH-500, Nuaillé, France) and 1% penicillin–streptomycin
(Gibco 15-140-122, United States), and maintained at 37◦C
with 5% CO2 levels. For conditioning, cells were cultured
in RPMI supplemented with 1% penicillin–streptomycin
and 10% EV-depleted FBS. FBS was depleted of bovine EVs
by ultracentrifugation at 100,000 g for 140 min. For the
preparation of the conditioned medium, 1 × 106 PAN02 cells
were seeded in 150 mm culture dishes containing 20 ml of
medium, and the conditioned medium was collected after
72 h of culture.
EV Isolation
The EV isolation/purification procedure was performed as
previously described (Ferreira et al., 2019). Specifically, the
conditioned medium was submitted to two initial centrifugations
(10 min, 500 g and 20 min, 3,000 g) to remove any suspended
or dead cells in the medium. To remove large EVs, media was
centrifuged (20 min, 12,000 g) and the pellet was discarded. The
supernatant enriched in small EVs was again centrifuged (2 h
20 min, 100,000 g), and the EV-enriched pellet was collected. For
sucrose cushion purification, this pellet was resuspended in 14 ml
filtered phosphate buffered saline (PBS, Corning 15313581, NY,
United States) and added to the top of 4 ml sucrose solution
(D2O containing 1.2 g of protease-free sucrose and 96 mg of
Tris base adjusted to pH 7.4). A new ultracentrifugation was
performed (1 h 10 min, 100,000 g), after which 4 ml of the
sucrose fraction was collected using a 18G needle placed at the
bottom of the ultracentrifugation tube (away from the pellet).
Finally, 16 ml of PBS was added to the collected sucrose/EV
solution and an overnight (16 h, 100,000 g) ultracentrifugation
was performed. The pellet containing the isolated EVs was
resuspended in filtered PBS.
All solutions used (PBS and sucrose cushion) were
sterile (0.22 µm membrane-filtered). All centrifugation
steps were performed in refrigerated conditions (10◦C),
and ultracentrifugation was performed with rotors 50.4Ti or 70Ti
(Beckman-Coulter, CA, United States).
EV Labeling
For EV-tracking experiments, purified EVs were fluorescently
labeled using PKH67 membrane dye (PKH67GL-1KT, Sigma-
Aldrich, Germany). The staining was performed during the
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isolation protocol according to the manufacturer’s instructions.
Briefly, labeling was done before the sucrose cushion step. After
the fraction with labeled EVs (4 ml) was collected, the isolation
protocol was performed as previously stated.
EV Characterization
All EV samples were analyzed for particle concentration and size
distribution by the NS300 Nanoparticle Tracking Analysis (NTA)
system with red laser (638 nm) (NanoSight – Malvern Panalytical,
United Kingdom). Samples were prediluted in filtered PBS to
achieve a concentration within the range for optimal NTA
analysis. Video acquisitions were performed using a camera level
of 16 and a threshold between 5 and 7. Five to nine videos
of 30 s each were captured per sample. Analysis of particle
concentration per milliliter and size distribution were performed
with the NTA software v3.4.
Additionally, protein quantification of the EV preparations
was assessed by BCA assay (PierceTM BCA Protein Assay kit,
Thermo Fisher Scientific).
EV Treatment
All mouse work was performed in accordance with national
animal experimentation guidelines (DGAV), animal protocol
0421/000/000/2018. Adult C57Bl/6 female mice (5 to 8 weeks
old) were used for all experimental procedures. Mice were
anesthetized using isoflurane 1.5–3%. Five micrograms of EVs
were injected into the retro-orbital venous sinus in a total
volume of 100 µl filtered PBS. For education experiments,
mice received 5 µg of EVs every other day, three times per
week for 3 weeks. In the experiments involving evaluation
of EV incorporation, labeled EVs were injected 24 h prior
to tissue collection, and analysis of EV+ cells was performed
by flow cytometry or immunofluorescence. Unlabeled EVs
were used as controls for signal specificity. For education
experiments, retro-orbital injection of PBS was used in the
control groups.
Flow Cytometry Analysis
For tracking of labeled EVs and phenotypical analysis of murine
organs, femurs were flushed and single-cell suspensions were
filtered through a 40-µm strainer. Cells were washed in PBS
with 1% BSA and incubated with anti-CD11b-PerCP-Cyanine5.5
(clone M1/70, 1:100, BD Biosciences – 561114) at predetermined
saturating concentrations. PKH67-labeled EV-positive cells were
detected using blue laser excitation and 488 nm emission.
Data for 1,000,000 cells was acquired on a BD FACS CantoTM
cytometer with Diva software (BD) and was analyzed using
FlowJoTM software (TreeStar).
Collection of BM-Derived Cells and
CD11b+ Magnetic Sorting
C57Bl/6 female mice were euthanized and femurs and tibiae
were harvested and cleaned. The bones were flushed with cold
working buffer (PBS supplemented with 0.5% BSA and 2 mM
EDTA), using a 26G needle. The preparation was resuspended
using a 18G needle and filtered through a 40-µm strainer. The
single-cell preparation was then centrifuged (500 g, 10 min, 4◦C)
and the resulting pellet resuspended in ACK buffer. After 2 min
at room temperature, the lysis was stopped by adding more
working buffer and the sample was centrifuged (500 g, 10 min,
4◦C). The pellet was resuspended in working buffer and the
cells were counted.
Subsequently, cells underwent MACS bead isolation using
CD11b microbeads (Miltenyi Biotec, 130-049-601, Germany),
which enabled the isolation of CD11b+ cells from the
preparation. The CD11b+ cells were counted and centrifuged
(500 g, 10 min, 4◦C) and the pellet proceeded for RNA isolation.
RNA Extraction and cDNA Preparation
Prior to RNA extraction, CD11b+ BM cells were run through
the QIAshredder kit (79654, Qiagen, Germany). Total RNA was
isolated using the RNeasy Mini kit (74104, Qiagen), following
the manufacturer’s instructions, and resuspended in nuclease-
free water. RNA concentration and purity were estimated
by spectrophotometric absorbance (260 and 280 nm) using
a Nanodrop 2000 unit (Thermo Scientific). One microgram
of RNA was used to prepare cDNA using the QuantiTect




To analyze the genes whose expression was altered in mouse
CD11b+ BM cells as a result of education with PAN02 EVs,
animals were grouped between the ones educated with PAN02
EVs and the control animals educated with PBS. Total RNA
was then isolated as described above, and the RNA quality was
assessed using Bioanalyzer. The cDNA library was generated
using Kappa Stranded Total RNA with Ribo-Zero Library
Preparation Kit. The resultant DNA fragments (DNA library)
were sequenced in the Illumina HiSeq 4000 platform, using
150 bp paired-end sequencing reads.
For the analysis of differentially expressed genes, we used
the Differential Expression for RNA-Seq tool, which is a
multifactorial statistical analysis tool based on a negative
binomial model. It uses a generalized linear model approach
influenced by the multifactorial EdgeR method (Robinson et al.,
2009). The differentially expressed genes were filtered using
standard conditions (van Iterson et al., 2010; Raza and Mishra,
2012), and the genes that fulfilled both conditions were listed
in the results (Supplementary Table 1). The conditions were as
follows: fold change (≥ 2 or≤−2) and false discovery rate (FDR)
P-value ≤ 0.05.
Primer Design
The primers used in this study were designed using
Integrated DNA Technologies online software PrimerQuest
Tool (Integrated DNA Technologies, Inc., United States).
Primer sequences and characteristics are shown in
Supplementary Table 2.
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The amplification efficiencies of each selected gene performing
quantitative RT-PCR (RT-qPCR) were evaluated using cDNA
dilutions (1, 1:10, 1:100, 1:1,000, 1:10,000). The amplification
efficiency E of all primers used was measured and all displayed
high E-values ranging from 1.8 to 2.2 (Supplementary Table 2).
RT-qPCR Assay and Analysis
The qRT-PCR reactions were performed in a CFX96 Touch
Real-Time PCR Detection System thermocycler (Bio-Rad,
United States). The reaction mix was performed using 10 µl
SsoFast EvaGreen Supermix (1725200, Bio-Rad), primers at a
final concentration of 500 nM, 1 µl of cDNA, and nuclease-
free water to complete a final volume of 20 µl. After PCR, a
melting curve program from 65 to 95◦C with 0.5◦C changes was
applied, and the presence of a single reaction product in each
well was confirmed. All reactions were performed in duplicate
and technical replicates were run on the same plate. For the
analysis, the threshold value used for each plate was the one
defined by the software.
The relative expression was calculated using the model
proposed by M.W. Pfaffl (2001) and normalized to both Gapdh
and Hmbs levels, the two reference genes used.
Mass Spectrometry
Peptide Sample Preparation
The protein solution containing SDS and dithiothreitol (DTT)
was loaded onto filtering columns and washed exhaustively with
8 M urea in HEPES buffer (Wisniewski et al., 2009). Proteins were
reduced with DTT and alkylated with IAA. Protein digestion
was performed by overnight digestion with trypsin sequencing
grade (Promega).
Nano-LC-MSMS Analysis
Peptide samples were analyzed by nano-LC-MSMS (Dionex
RSLCnano 3000) coupled to a Q-Exactive Orbitrap mass
spectrometer (Thermo Scientific). Briefly, the samples (5 µl)
were loaded onto a custom-made fused capillary precolumn
(2 cm length, 360 µm OD, 75 µm ID) with a flow of 5 µl
per min for 7 min. Trapped peptides were separated on a
custom-made fused capillary column (20 cm length, 360 µm
outer diameter, 75 µm inner diameter) packed with ReproSil-Pur
C18 3-µm resin (Dr. Maish, Ammerbuch-Entringen, Germany)
with a flow of 300 nl per minute using a linear gradient from
92% A (0.1% formic acid) to 28% B (0.1% formic acid in 100
acetonitrile) over 93 min followed by a linear gradient from 28
to 35% B over 20 min at a flow rate of 300 nl per minute.
Mass spectra were acquired in positive ion mode applying
automatic data-dependent switch between one Orbitrap survey
MS scan in the mass range of 400 to 1,200 m/z followed by
higher-energy collisional dissociation (HCD) fragmentation and
Orbitrap detection of the 15 most intense ions observed in the
MS scan. Target value in the Orbitrap for MS scan was 1,000,000
ions at a resolution of 70,000 at m/z 200. Fragmentation in the
HCD cell was performed at normalized collision energy of 31 eV.
Ion selection threshold was set to 25,000 counts and maximum
injection time was 100 ms for MS scans and 300 and 500 ms
for MSMS scans. Selected sequenced ions were dynamically
excluded for 45 s.
Database Search
The obtained data from the X LC-MS runs were searched
using VEMS (Matthiesen et al., 2012; Carvalho et al., 2014)
and MaxQuant (Cox and Mann, 2008). A standard proteome
database from UniProt (3AUP000005640), in which common
contaminants were included, was also searched. Trypsin cleavage
allowing a maximum of four missed cleavages was used.
Carbamidomethyl cysteine was included as fixed modification.
Methionine oxidation, N-terminal protein acetylation, and S, T,
and Y phosphorylation were included as variable modifications;
5 ppm mass accuracy was specified for precursor ions and 0.01
m/z for fragment ions. The FDR for protein identification was
set to 1% for peptide and protein identifications. No restriction
was applied for minimal peptide length for VEMS search.
Identified proteins were divided into evidence groups as defined
(Matthiesen et al., 2012).
Negative-Staining Transmission Electron
Microscopy
Extracellular vesicles were visualized by transmission electron
microscopy (TEM) using negative staining. For this, 10 µl of
the sample solution was mounted on formvar/carbon film-coated
mesh nickel grids (Electron Microscopy Sciences, Hatfield, PA,
United States). The excess liquid was removed with filter paper,
and 10 µl of 1% uranyl acetate was added onto the grids.
Visualization was carried out on a JEOL JEM 1400 TEM at 120 kV
(Tokyo, Japan). Images were digitally recorded using a CCD
digital camera (Orious 1100W Tokyo, Japan).
Statistical and Pathway Analysis
Error bars in graphical data represent means ± SEM. Statistical
significance was determined using a two-tailed Student’s t-test or
by ANOVA. P < 0.05 was considered statistically significant.
Statistical analyses were performed using the GraphPad Prism
software (GraphPad software). No statistical method was
used to predetermine sample size. The experiments were not
randomized, and the investigators were not blinded to allocation
during the experiments and outcome assessment.
Accession Codes
The raw sequencing data (Supplementary Table 1) have
been deposited in the GEO database under accession
number GSE156071.
RESULTS
Isolated EVs were characterized for morphology and size by
transmission electron microscopy (Figure 1A) and for size
distribution by Nanoparticle Tracking Analysis (Figure 1B)
and the expression of proteins commonly identified in EVs
(Figure 1C). Currently, there are no available methods to isolate
EVs expressing endosomal features and consensus on markers
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FIGURE 1 | Pancreatic cancers-derived EVs binding to BM cells. (A) Representative transmission electron microscopy of PAN02 EVs. (B) Representative
Nanoparticle Tracking Analysis of PAN02 EVs. (C) Proteins frequently present and absent in small EVs, studied in PAN02 EVs by Protein Mass Spectrometry.
(D) PC-EVs are taken up by liver and BM cells, 24 h post-injection. (E) Most of the cells that take up PC-EVs are CD11b+ BM cells. (F) Three-week education with
PC-EVs does not modify the incidence of EV+ BM cells or CD11b+ cells within cells that take up PC-EVs (G). (H) Three-week education with PC-EVs induces the
increase of BM CD11b+ cells. **P < 0.01, ****P < 0.0001 by ANOVA.
that could be used to differentiate endosomal (i.e., exosomes)
from membrane shedding-derived vesicles (i.e., microvesicles). In
fact, even molecules considered as markers of small endosomal
EVs, such as HSP70, CD63, and CD9, have been reported
to be present both in small and large EVs (Kowal et al.,
2016). Therefore, although the majority of our vesicles display
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FIGURE 2 | Gene expression analysis of pancreatic cancer EV-treated bone marrow cells. (A) Volcano plot of RNA-Seq of PBS versus EV-treated CD11b+ BM cells
showing 13 and 28 genes significantly up- and downregulated (red dots and blue dots, respectively), with FDR P-value ≤ 0.05 and fold change > 2 or < −2. (B)
Graph plot of the most significant processes of Gene Ontology (GO) enrichment analysis in the “Biological Process” section of up- and downregulated genes, using
the Gene Ontology PANTHER Database.
exosome features, including size (Figures 1A,B) and molecular
composition (Figure 1C and Supplementary Table 3), we
decided to identify them as EVs throughout the manuscript
to avoid potential sample misidentification, following the latest
MISEV’s recommendations (Thery et al., 2018).
To first determine the occurrence of PC–BM interaction,
labeled PC-EVs were injected intravenously in mice. Besides the
liver, 24-h post-injection EVs were also located in the BM, albeit
the percentage of EVs+ cells in the BM was lower (∼0.02%) than
the one found in the liver (∼0.04%) (Figure 1D). In the BM,
more than 80% of the cells that took up PC-EVs were CD11b+
(Figure 1E). To our knowledge, this is the first report of a direct
PC–BM communication axis mediated by EVs.
To evaluate if this proportion increased over time and upon
continuous treatment, animals were also educated (3 weeks,
every other day) with PC-EVs. No differences in the percentage
of EVs+ BM cells were found throughout the experiment
(Figure 1F). The percentage of CD11b+ cells among EVs+
BM cells also did not oscillate throughout the experiment
(Figure 1G). However, education with PC-EVs increased
the percentage of CD11b+ BM cells at the experiment
endpoint (Figure 1H).
We next asked whether PC-EVs can modify the gene
expression profile of CD11b+ BM cells. For that, we
sequenced RNA samples extracted from CD11b+ BM cells
of both naive and PC-EV-educated mice. The expression
levels of all samples were assessed through the mapping
of the high-quality reads of each sample, where 88.9
to 94.38% of the total fragments were mapped against
the Mus musculus (GRCm38) genome. The differentially
expressed genes were selected using standard conditions
(FDR P-value ≤ 0.05 and fold change > 2 or < −2), which
yielded a total of 41 genes (Figure 2A). Of these, 13 genes
were significantly upregulated (Table 1) and 28 significantly
downregulated (Table 2). These results were validated by
qPCR analysis of two of the top differentially expressed genes
(Supplementary Figure 1).
Gene Ontology (GO) analysis revealed that the upregulated
genes (Table 1) were associated with immune response
processes and immunoglobulin production (Figure 2A). Among
those genes, we found the Immunoglobulin heavy constant
gamma 3 (fragment) (Ighg3) gene, which is associated with
the IgG3 isotype, and the genes Immunoglobulin heavy
constant alpha (fragment) (Igha) and Immunoglobulin
J chain (Jchain), both associated with IgA molecules.
Within the downregulated genes, we found that the most
significant GO processes were associated with transcriptional
activation, response to stimulus, and regulation of gene
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TABLE 1 | Upregulated genes.
Name FDR p-value Log2 fold change ENSEMBL
Immunoglobulin heavy variable 1-26 (Fragment) 0 4,623730851 ENSMUSG00000094546
Immunoglobulin kappa variable 4-59 (Fragment) 0 4,447764161 ENSMUSG00000094006
Immunoglobulin J chain 0 2,449246148 ENSMUSG00000067149
Immunoglobulin heavy constant alpha (Fragment) 0 1,927167042 ENSMUSG00000095079
Immunoglobulin kappa constant (Fragment) 0 1,914161392 ENSMUSG00000076609
Ig gamma-1 chain C region secreted form (Fragment) 1,30134E-06 2,752343692 ENSMUSG00000076614
Predicted gene, 49345 (Fragment) 3,1653E-05 2,99697945 ENSMUSG00000114923
Immunoglobulin heavy variable V3-8 (Fragment) 0,000129751 4,808095452 ENSMUSG00000076674
Immunoglobulin kappa variable 1-110 (Fragment) 0,004373421 3,110850502 ENSMUSG00000093861
U3A small nuclear RNA 0,014852817 2,027515231 ENSMUSG00000106147
Immunoglobulin lambda constant 1 (Fragment) 0,021654529 1,776317776 ENSMUSG00000105906
Immunoglobulin lambda variable 1 (Fragment) 0,041671894 1,728395758 ENSMUSG00000076934
Immunoglobulin heavy constant gamma 3 (Fragment) 0,044897113 2,031085382 ENSMUSG00000076615
TABLE 2 | Downregulated genes.
Name FDR p-value Log2 fold change ENSEMBL
Nuclear receptor subfamily 4 group A member 1 2,19745E-07 −1,435869584 ENSM USG 00000023034
Lipoprotein lipase 2,74851E-07 −1,09850161 ENSMUSG00000015568
Cyclic AMP-dependent transcription factor ATF-3 4,81325E-07 −1,887929851 ENSM USG 00000026628
ATP synthase protein 8 9,71391E-06 −1,554520723 ENSM USG 00000064356
Early growth response protein 3 6,39601E-05 −1,565012389 ENSM USG 00000033730
Krueppel-like factor 4 9,72554E-05 −1,036425344 ENSM USG 00000003032
Early growth response protein 1 0,000369143 −1,293024511 ENSMUSG00000038418
Prostaglandin G/H synthase 2 0,000573753 −1,548440352 ENSM USG 00000032487
Probable leucine–tRNA ligase, mitochondrial 0,000590408 −1,422122013 ENSM USG 00000035202
Regulator of G-protein signaling 1 0,001504139 −1,862241816 ENSM USG 00000026358
Monocyte differentiation antigen CD14 0,001783497 −1,048560286 ENSMUSG00000051439
C-C motif chemokine 3 0,003368206 −1,210768022 ENSM USG 00000000982
Predicted gene, 47075 0,0046162 −2,554952242 ENSMUSG00000114169
Cyclin-dependent kinase inhibitor 1 0,005512827 −1,012425917 ENSM USG 00000023067
Proto-oncogene c-Fos 0,005961159 −1,078598039 ENSMUSG00000021250
Transcription factor Spi-C 0,009588443 −1,02746831 ENSM USG 00000004359
Fos-related antigen 1 0,009676491 −1,304846194 ENSMUSG00000024912
Nuclear receptor subfamily 4 group A member 2 0,013476224 −1,63691541 ENSM USG 00000026826
Predicted gene, 23262 0,013476224 −3,507668615 ENSM USG 00000088948
Predicted gene 6377 0,014852817 −1,716519183 ENSM USG 00000048621
X-linked lymphocyte-regulated protein PM1 0,020080701 −1,997616005 ENSM USG 00000054626
C-C motif chemokine 2 0,021654529 −1,882312446 ENSM USG 00000035385
Predicted gene, 47088 0,026317916 −2,725652374 ENSMUSG00000113076
Predicted gene, 48275 0,031964977 −8,738521219 ENSMUSG00000111202
E3 SUMO-protein ligase EGR2 0,033340755 −1,358834793 ENSM USG 00000037868
Hematopoietic prostaglandin D synthase 0,041671894 −1,012816032 ENSMUSG00000029919
Predicted gene 45053 0,043671552 −1,376757203 ENSMUSG00000108368
Mitochondrially encoded 16S rRNA 0,043671552 −1,896767497 ENSM USG 00000064339
expression (Figure 2B). Specifically, most downregulated
genes were transcription factors associated with monocyte
and macrophage differentiation, macrophage polarization,
production of pro- or anti-inflammatory cytokines, and
immune cell trafficking (Table 2). Interestingly, the
majority of downregulated genes are relevant in the tumor
microenvironment context.
DISCUSSION
In the present study, we aimed to identify a novel systemic
cell–cell communication axis with potential relevance to tumor
microenvironment dynamics. Previously, we have demonstrated
that PC-derived EVs can induce a liver microenvironment
supportive of tumor development and metastasis, LPMN, by
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acting in non-tumor cells in the liver. The LPMN cascade of
events involves the accumulation of CD11b+ BM cells in the liver,
which is associated with the formation of hepatic PC metastatic
lesions (Costa-Silva et al., 2015). For this reason, we asked if
EVs could also mediate a direct communication between PC
and CD11b+ BM cells in vivo. We found that PC-EVs bind
preferentially to CD11b+ BM cells and induce the expansion of
this cell population upon 3 weeks of treatment, every other day
with PC-EVs. These results agree with previous reports of EVs
mediating the communication of other cancer types and BM (Yu
et al., 2007; Peinado et al., 2012).
We next showed that PC-EVs can reprogram the gene
expression of recipient CD11b+ BM cells. Indeed, various studies
describe tumor EVs as capable of impacting myeloid cell function
(Valenti et al., 2006; Yu et al., 2007; Shen et al., 2017) whereas
PC-EVs were shown to regulate the expression of TLR4 in
dendritic cells in vitro (Zhou et al., 2014). EVs carry all main
biomolecules, including lipids, metabolites, proteins, and/or
nucleic acids, which can impact the recipient cells and mediate
several biological processes such as tumor growth and invasion,
inflammation, and immunologic remodeling. Various studies
describe the role of EV lipids, namely PGE2, in tumor growth
and resistance (Record et al., 2018). The role of metabolites
transported by EVs cannot be dismissed since EVs derived
from MSCs are packaged with numerous metabolites that have
been directly associated with immunomodulation, including
M2 macrophage polarization and regulatory T lymphocyte
induction (Showalter et al., 2019). Worth mentioning is also
the role of microRNA within EVs, since mir-145 can regulate
the polarization of tumor-associated macrophages (Shinohara
et al., 2017). In the past, we also described the relevance of the
protein content in tumor EV bioactivity, when we described
that once taken up by hepatic resident macrophages, in a
mechanism mediated by EV Integrin αVβ5 (Hoshino et al.,
2015), pancreatic cancer-derived EVs containing high levels of
MIF (Costa-Silva et al., 2015) induced upregulation of secreted
factors associated with liver fibrosis, such as TGF-β (Costa-
Silva et al., 2015), and pro-inflammatory genes involved with
metastasis, such as S100A8 and S100P (Lukanidin and Sleeman,
2012; Hoshino et al., 2015). Considering the literature on
this topic, we expect that the response of CD11b BM cells
to PC-EVs described in this manuscript most likely involves
numerous molecules and different pathways, suggesting that it
could be simultaneously mediated by multiple EV biomolecules.
Our work did not evaluate in vivo the potential role of the
genes differentially expressed in BM CD11b+ cells upon PC-EV
education in the setup of prometastasis hepatic niches. Therefore,
follow-up in vivo studies will be necessary to test the potential
role of each of the identified genes in PC liver metastasis.
Future investigation will enable the identification of which
EV biomolecules mediate the transcription reprogramming
here described. In addition, based on previous works that
utilized plasma EVs as biomarkers for diagnosis, prognosis,
and follow-up of cancer patients (Peinado et al., 2012; Costa-
Silva et al., 2015; Hoshino et al., 2015, 2020; Melo et al.,
2015), it is possible that EV biomolecules linked with PC-
CD11b+ BM cell communication may enable early detection
of this process through the study of circulating plasma EVs.
We will here discuss on genes regulated by PC-EVs with
potential relevance to tumor microenvironments and the biology
of monocytes/macrophages.
Immunoglobulin Genes
The production of immunoglobulins has been classically linked
to lymphoid B cells. However, recent evidence challenged the
existing dogma by showing expression of immunoglobulins
outside the lymphoid lineage (e.g., monocytes and macrophages)
in oncologic settings (Haziot et al., 2018; Busch et al.,
2019). These works describe immunoglobulin expression as a
defining feature of monocytes and also macrophages in the
tumor microenvironment.
Increased levels of immunoglobulin expression in tumor
microenvironments are described to result in the accumulation
of immune complexes that favor tumor-promoting inflammatory
responses, including recruitment and activation of several
myeloid cell types (Barbera-Guillem et al., 1999). Both IgG
and IgA are relevant in the tumor microenvironment, having
anti- and protumoral effects. IgG is described to promote
cell growth and metastasis, inhibit apoptosis, and play a role
in cancer immune evasion (Wan et al., 2015; Xu et al.,
2016). Synergistically, IgG and tumor cell-derived debris are
able to promote metastasis of pancreatic cancer by inducing
inflammation via M2-polarized tumor-associated macrophages
(TAMs) (Chen et al., 2019). Moreover, IgGs have been
shown to promote cancer development by activating Fc-
γ receptors on resident and recruited leukocytes that in
turn regulate recruitment, composition, and effector functions
of tumor-infiltrating lymphocytes in a mouse model of
squamous carcinogenesis (Andreu et al., 2010). On the other
hand, some studies show IgG1 supporting immunity against
tumors, inducing antibody-dependent cell-mediated cytotoxicity
(ADCC) and antibody-dependent cellular phagocytosis (ADCP)
(Kellner et al., 2017).
It has also been shown that IgA can block cytotoxic T-cell
reactions against melanoma (O’Neill and Romsdahl, 2009).
More recently, IgA+ plasmocytes were shown to suppress
antitumor immunity in a mouse prostate cancer model.
However, in this study, it is unclear if the suppression can be
attributed to IgA+ plasmocytes or IgA alone (Shalapour et al.,
2015). By contrast, IgA shows a therapeutic potential against
cancer cells, since it activates neutrophil-mediated antibody-
dependent cellular cytotoxicity better than IgG (Frontera et al.,
2018; Steffen et al., 2020). It should be highlighted though
that confirmation that immunoglobulins produced by non-
lymphoid cells are functional is still pending, since studies
on whether affinity-matured antibodies from these cells are
capable of binding to antigens are not yet available. Additionally,
we cannot exclude the potential presence of B1 cells, a
small immunoglobulin-expressing phagocytic population that is
believed to originate from B cells, within our CD11b+ BM cells
(Griffin and Rothstein, 2011).
In light of these findings, and taking into consideration the
previously described direct association between CD11b+ BM
cell accumulation in the liver and the formation of hepatic
PC metastatic lesions, our results suggest that PC-EV-induced
immunoglobulin expression on CD11b+ BM cells may play a
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role in PC liver metastasis. Nevertheless, it is still unclear which
specific epitopes are recognized by these antibodies and whether
they contribute to tumor microenvironments (Haziot et al., 2018;
Busch et al., 2019).
Genes Linked With
Monocyte/Macrophage Differentiation
Among the downregulated genes identified, lipoprotein lipase
(Lpl) (Chang et al., 2018), transcription factor Spi-c (Spic)
(Kohyama et al., 2008; Haldar et al., 2014; Alam et al.,
2017; Kurotaki et al., 2017), and Nuclear receptor subfamily
4 group A member1 (Nr4a1) (Hanna et al., 2011) have all
been previously found to induce differentiation of monocytes.
Another gene potentially linked with monocyte/macrophage
differentiation is CDK inhibitor 1, which when downregulated
leads to higher expression of CD11b, thus modifying cellular
differentiation (Radomska et al., 2012; McClure et al., 2016).
Other downregulated genes, early growth response protein
1 (Egr1) and 3 (Egr3), were believed to have an essential
role in regulating monocyte/macrophage differentiation, but
were later suggested to have no impact in the macrophage
differentiation process (Carter and Tourtellotte, 2007). Hence,
our results suggest a mixed effect of PC-EVs in CD11b+ BM
cell differentiation, with some of the downregulated genes found
having a positive impact on the differentiation process and others
having a negative impact in the same process. A more detailed
functional characterization will thus be necessary to understand
the final balance of the downregulation of these genes by PC-EVs
in CD11b+ BM cell differentiation, as well as their role in PC.
Genes Linked With Tumor Immunity
In the establishment of tumor-supportive microenvironments,
macrophage polarization is pivotal. Reduced expression of Cyclic
AMP-dependent transcription factor ATF-3 (Atf3) (Labzin et al.,
2015; Sha et al., 2017), Fos-related antigen 1 (Fosl1) (de Marcken
et al., 2019), and Nr4a1 (Hamers et al., 2016) can impact
pro-inflammatory M1 polarization and antitumor immunity
(Kratochvill et al., 2015; Chiba et al., 2018), as they negatively
regulate these processes. C-C chemokine ligand 3 (Ccl3) (Cassol
et al., 2009) was also reported to be involved in the M1
macrophage polarization and CD14 was shown not only to
contribute to a M1 phenotype but also to drive strong Th1/Th17
signaling in macrophages and circulating dendritic cells (Prakash
et al., 2016). Reduced expression of the Proto-oncogene c-Fos
(c-fos) and Egr1 is expected to reduce the expression of pro-
inflammatory and antitumoral cytokines, which are also involved
in the M1 polarization (Krämer et al., 1994; Ray et al., 2006;
Maruyama et al., 2007; Cullen et al., 2010; Hop et al., 2018;
Yu et al., 2018). Conversely, reduced expression of Atf3 (Sha
et al., 2017), Klf4 (Ahmad et al., 2018; Wen et al., 2019), and
Prostaglandin G/H synthase 2 (Pghs-2) (Wang X. et al., 2017)
in macrophages can favor a pro-inflammatory M1 polarization,
hence potentially favoring antitumoral responses.
On the other hand, some of the genes downregulated by PC-
EVs were also found to support tumor development, as C-C
chemokine ligand 2 (Ccl2) (Roca et al., 2009; Li et al., 2017),
Atf3 (Sha et al., 2017), Hematopoietic prostaglandin D synthase
(Abbas and Janeway, 2000), Krüppel-like factor 4 (Klf4) (Kapoor
et al., 2015; Wang K. et al., 2017), Nuclear receptor subfamily 4
group A member 2 (Nr4a2) (Mahajan et al., 2015), and Pghs-2 (Li
et al., 2015) were linked to M2 polarization of macrophages. The
Egr2 gene has been described as a M2 macrophage marker and it
has been implicated in fate determination in the myeloid lineage
(Gabet et al., 2010; Jablonski et al., 2015). Specifically, an Egr2
knockdown model failed to show upregulation of either M1 or
M2 markers upon stimulation, and low levels of Egr2 expression
were associated with non-responsiveness of macrophages to
activation signals (Veremeyko et al., 2018).
Besides the discussed effects on M1/M2 macrophage
polarization, several of the downregulated genes were associated
with other antitumoral effects, which may lead to a broader range
of protumorigenic outcomes. That is the case of Nr4a1, Ccl2,
and Ccl3, which antagonize tumor growth by attracting tumor-
suppressive immune cells. Indeed, infiltration of inflammatory
cells in the tumors of Nr4a1−/− mice was diminished when
compared with Nr4a1+/+ mice (Ahmad et al., 2017), and the
inhibition of Ccl2 promoted neocarcinogenesis and metastasis
(Huang et al., 1994; Li et al., 2014; Lavender et al., 2017). Ccl2
(Granot et al., 2011; Mitchem and DeNardo, 2012) has also
been reported to increase the cytotoxicity of neutrophils against
tumor cells. Thus, reduction of Ccl2 expression can decrease
neutrophil-mediated killing of tumor cells and promote a
protumorigenic microenvironment.
We here suggest that the downregulation of these genes by PC-
EVs could induce a combined anti-/protumorigenic response by
BM CD11b+ cells. Additional in vivo studies will be necessary
to evaluate whether these inflammatory profiles will be reversed
and/or reinforced after the influx of these cells in the liver, where
Kupffer cell-derived TGF-β (Costa-Silva et al., 2015) can play a
potential role in inducing protumorigenic genes (Gratchev, 2017)
by BM-derived CD11b+ cells.
Genes Linked With
Monocyte/Macrophage Trafficking
Genes associated with monocyte and macrophage recruitment,
such as Ccl2 (Qian et al., 2011; Carson et al., 2017; Gschwandtner
et al., 2019), Ccl3 (Ntanasis-Stathopoulos et al., 2020), and
Fosl1 (Jiang et al., 2019), were found to be downregulated.
The decrease in the levels of Fosl1, Ccl2, and Ccl3 is expected
to reduce the recruitment of cells that allow tumor cells
to evade the immune surveillance, e.g., TAMs, regulatory T
cells (Tregs), and myeloid-derived suppressor cells (MDSCs)
(Jiang et al., 2019; Wculek et al., 2019; Ntanasis-Stathopoulos
et al., 2020). Furthermore, downregulated Ccl3 could reduce the
recruitment of cytotoxic neutrophils, dendritic cells, and NK
cells; reduce CD8+ antitumor response; and lead to impaired
antigen presentation, reduced levels of IFN-γ by antigen-specific
T cells, and consequently, reduced cytotoxic activity (Song et al.,
2007; Ntanasis-Stathopoulos et al., 2020). Overall, a decrease in
the recruitment of monocytes and macrophages could shape the
tumor microenvironment toward a less supportive setting for
cancer progression.
Another downregulated gene, Atf3, has been linked with
increased intrahepatic macrophage/neutrophil trafficking
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(Zhu et al., 2018). Regulator of G-protein signaling 1 (Rgs1),
also downregulated by PC-EVs, has been involved in the
chemoattraction of monocytes. Specifically, Rgs1 deactivates the
chemotactic response (Denecke et al., 1999), and its deficiency
leads to enhanced recruitment of macrophages (Patel et al.,
2015). We speculate that the Rgs1 downregulation in CD11b+
BM cells can lead to less myeloid accumulation and more
monocyte/macrophage trafficking.
In most of these studies, genes were downregulated in the
whole animal, instead of only in BM cells. Therefore, more
detailed in vivo experiments would be needed to test whether
reduced expression of these genes in CD11b+ BM cells could
impact their trafficking to PC microenvironments.
Genes Linked With
Monocyte/Macrophage Apoptosis
The downregulation of Ccl2 (Salcedo et al., 2000; Lavender
et al., 2017), Fosl1 (Lewçn et al., 2007; Luo et al., 2009), and
Rgs1 (Hu et al., 2019) has been described to increase apoptosis
and to decrease angiogenesis and tumor invasion by affecting
molecules associated with these processes (e.g., VEGF, MMP-
2, MMP-9). On the other hand, the downregulated genes Egr1
(Chen et al., 2010) and Atf3 (Wong, 2011) have been described
as proapoptotic, and thus, the decrease in their expression alone
might provide a higher degree of protection against apoptosis in
CD11b+ BM cells.
CONCLUSION
We here found a novel PC–BM communication axis mediated by
PC-EVs. Our gene expression analysis showed reprogramming
of genes linked to both anti- and protumorigenic activities
by CD11b+ cells. Their potential relevance in PC tumor
microenvironments was discussed, although how the individual
effects of the reprogrammed genes balance each other to a final
anti- or protumorigenic effect is currently unclear. Future in vivo
studies involving single-cell transcriptome and detailed analysis
of the role of each gene in the phenotype of CD11b+ BM cells will
be necessary to clarify whether and how PC-EVs uptake by these
cells contributes to the setup of PC microenvironments. Stepping
further into the future, the study of PC-educated BM-derived
cells linked with PC metastasis in the peripheral blood could
be used as a minimally invasive method to detect and monitor
these protumorigenic niches in clinical settings, thus having a
potential impact in improving early diagnosis, treatment, and
follow-up of patients with PC and other oncologic diseases.
Additionally, it has the potential to contribute to the development
of therapeutic targeting of BM-derived cells that promote liver
metastatic disease.
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